# Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma

> **NCT07658872** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sichuan University** · enrollment: 120 (estimated)

## Conditions studied

- Gastric Adenocarcinoma
- Esophagogastric Junction Adenocarcinoma

## Interventions

- **DRUG:** fruquintinib + sintilimab + SOX
- **DRUG:** Sinitilimab+SOX

## Key facts

- **NCT ID:** NCT07658872
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2027-05-19
- **Final completion:** 2028-04-06
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07658872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07658872, "Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07658872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*